Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc.: Pioneering Novel Cancer Therapies
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company dedicated to transforming the oncology treatment landscape through innovative therapies. Headquartered in Newton, Massachusetts, Karyopharm is at the forefront of developing and commercializing Selective Inhibitor of Nuclear Export (SINE) compounds, a groundbreaking approach targeting nuclear export dysregulation—a critical mechanism in cancer progression. Since its founding, the company has been committed to addressing high unmet medical needs in oncology.
Core Technology and Lead Product: XPOVIO® (Selinexor)
Karyopharm's flagship product, XPOVIO® (selinexor), is the first FDA-approved oral exportin 1 (XPO1) inhibitor. This first-in-class therapy selectively binds to and inhibits XPO1, a protein responsible for exporting tumor suppressor proteins from the nucleus, thereby restoring their function and inducing cancer cell death. XPOVIO has received regulatory approval for multiple oncology indications, including:
- In combination with Velcade® (bortezomib) and dexamethasone for adult patients with multiple myeloma after at least one prior therapy.
- In combination with dexamethasone for heavily pretreated multiple myeloma patients.
- As a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two lines of systemic therapy.
Additionally, XPOVIO (marketed as NEXPOVIO® in certain regions) has gained regulatory approvals in numerous countries, including Europe, the United Kingdom, China, South Korea, and Canada, through strategic partnerships with global pharmaceutical companies.
Pipeline and Research Focus
Karyopharm is advancing a robust pipeline of clinical trials targeting high unmet-need cancer indications. Key areas of focus include:
- Endometrial Cancer: The Phase 3 XPORT-EC-042 trial evaluates selinexor as a maintenance therapy for TP53 wild-type advanced or recurrent endometrial cancer.
- Myelofibrosis: The Phase 3 SENTRY trial explores selinexor in combination with ruxolitinib for JAK inhibitor-naïve patients.
- Other Indications: Ongoing studies include multiple myeloma and additional hematologic malignancies.
Revenue Streams and Global Presence
Karyopharm primarily generates revenue through U.S. sales of XPOVIO, complemented by licensing and milestone payments from international partners. Its strategic collaborations with companies like Menarini and Antengene facilitate the global distribution of its products, expanding its reach to markets in Asia, Europe, and beyond.
Challenges and Competitive Landscape
Operating in the highly competitive oncology pharmaceutical industry, Karyopharm faces challenges such as regulatory complexities, competition from established therapies, and the financial burden of clinical trials. Key competitors include major pharmaceutical companies developing treatments for similar indications. However, Karyopharm's unique focus on nuclear export dysregulation and its first-mover advantage with XPOVIO position it as a distinctive player in the market.
Commitment to Patients and Innovation
Driven by a mission to improve the lives of cancer patients, Karyopharm combines scientific innovation with a patient-centric approach. Its dedication to pioneering therapies addressing critical medical needs underscores its role as a transformative force in oncology.
Karyopharm Therapeutics (Nasdaq: KPTI) reported strong financial results for Q4 2021, with net product revenue of $29.8 million, a 47% increase year-over-year. Total revenue for 2021 reached $209.8 million, up from $108.1 million in 2020. They achieved significant milestones, including a commercialization partnership with Menarini and positive data from the SIENDO study on selinexor. However, the company reported a net loss of $124.1 million for 2021. For 2022, Karyopharm expects XPOVIO revenue between $135 million and $145 million.
Karyopharm Therapeutics (Nasdaq: KPTI) reported positive results from its Phase 3 SIENDO study on selinexor for patients with advanced or recurrent endometrial cancer. The study involved 263 patients and achieved a median progression-free survival (PFS) of 5.7 months with selinexor, compared to 3.8 months for placebo, marking a 50% improvement. The drug showed a 30% reduction in disease progression risk. Particularly, patients with wild-type p53 saw a median PFS of 13.7 months. Karyopharm plans to submit a supplemental New Drug Application to the FDA in H1 2022.
Karyopharm Therapeutics (KPTI) will report its fourth quarter and full year 2021 financial results on February 8, 2022. Management will hold a conference call at 8:30 a.m. ET on the same day to discuss the results and updates. Karyopharm is known for its novel cancer therapies, including the first-in-class XPO1 inhibitor, XPOVIO®, and has a focused pipeline targeting high unmet needs in cancer treatments. Interested parties can access the call via phone or a live audio webcast on the company's website.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the grant of stock options for 124,500 shares to 15 newly-hired employees, effective January 31, 2022. The exercise price is set at $8.90 per share, reflecting the stock's closing price on the grant date. Options will vest over four years, with 25% vesting after one year and the remainder monthly. The options are also subject to immediate exercise if the employee's role is terminated without cause within a year following a 'change in control.' This move aligns with Nasdaq rules for inducements to new hires.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the FDA granted orphan drug designation for eltanexor, a novel oral SINE compound, aimed at treating myelodysplastic syndromes (MDS). This designation supports the development of therapies for conditions affecting fewer than 200,000 patients annually, offering incentives such as potential market exclusivity. Eltanexor has shown a 53% overall response rate in clinical trials for HMA-refractory MDS, significantly improving survival rates compared to standard treatments. Karyopharm remains focused on advancing its clinical trials to provide new options for patients.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that President and CEO Richard Paulson will present virtually at the B. Riley Securities Oncology Investor Conference on January 28, 2022, at 9:30 a.m. ET. Investors can access a live webcast of the presentation under the 'Events & Presentations' section of Karyopharm's website. The company specializes in innovative cancer therapies and is known for its lead compound, XPOVIO® (selinexor), which has received multiple regulatory approvals. For more details, visit www.karyopharm.com.
Karyopharm Therapeutics (Nasdaq: KPTI) has announced the promotion of Sohanya Cheng to Chief Commercial Officer, effective immediately. Cheng's role includes directing the company's commercial strategy, particularly the ongoing commercialization of XPOVIO® (selinexor). With 18 years of experience in oncology and significant contributions to Karyopharm's revenue increase in 2021, her leadership is anticipated to strengthen the company’s market position. Karyopharm continues to focus on expanding its oncology portfolio and preparing for forthcoming clinical trial results.
Karyopharm Therapeutics (Nasdaq: KPTI) reported preliminary unaudited net product revenues of approximately $29.7 million for Q4 2021 and $98.3 million for the full year. The company is focused on advancing its pipeline with upcoming results from the Phase 3 SIENDO study for selinexor in advanced endometrial cancer expected this quarter. Karyopharm aims to increase sales and adoption of XPOVIO in multiple myeloma and has partnered with Menarini for further commercialization. Notable 2021 achievements include gaining conditional marketing authorization in Europe and the UK for NEXPOVIO.
Karyopharm Therapeutics (Nasdaq: KPTI), a leader in cancer therapies, announced that CEO Richard Paulson will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11 at 3:45 p.m. ET. There will be a Q&A session at 4:05 p.m. ET. The presentation will be held virtually, and a live webcast, along with presentation slides, will be available on the company’s investor website for 30 days post-event. Karyopharm specializes in innovative treatments targeting nuclear export for cancer and other diseases.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options for 5,600 shares to two new employees, effective December 31, 2021. The options, priced at $6.43 per share, are part of an inducement package compliant with Nasdaq Listing Rule 5635(c)(4). Each option vests over four years, with a portion vesting upon the one-year employment anniversary. Immediate exercise is possible upon termination for good reason or without cause within a year of a change in control. Karyopharm focuses on developing innovative cancer therapies, notably XPOVIO®, for various malignancies.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
What is Karyopharm Therapeutics Inc.'s core focus?
What is XPOVIO® (selinexor)?
How does Karyopharm generate revenue?
What are Karyopharm's key clinical trials?
What makes Karyopharm unique in the oncology space?
